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Existing high-throughput methods to identify RNA-binding proteins (RBPs) involving 
capture of polyadenylated RNAs can not recover proteins that interact with non-
adenylated RNAs, including lncRNA, pre-mRNA and bacterial RNAs. We present 
orthogonal organic phase separation (OOPS) which does not require molecular tagging or 
capture of polyadenylated RNA. We verify OOPS in HEK293, U2OS and MCF10A human 
cell lines, finding 96% of proteins recovered are bound to RNA. We demonstrate that all 
long RNAs can be crosslinked to proteins and recover 1838 RBPs, including 926 putative 
novel RBPs. Importantly, OOPS is approximately 100-fold more efficient than current 
techniques, enabling analysis of dynamic RNA-protein interactions. We identified 749 
proteins with altered RNA binding following release from nocodazole arrest. Finally, 
OOPS allowed the characterisation of the first RNA-interactome for a bacterium, 
Escherichia coli. OOPS is an easy to use and flexible technique, compatible with 
downstream proteomics and RNA sequencing and applicable to any organism.  
 
Editors summary 
RNA-binding proteins can be identified and quantified in any organism using a simple 
method that combines UV crosslinking and phase separation.   
Introduction 
Interactions between RNA-binding proteins (RBPs) and RNA regulate transcription and 
transcript trafficking, decay and translation1Ð7 thereby modulating cell homeostasis and cell fate. 
Several approaches are available to characterise RNA-RBP interactions: Protein-Bound RNAs 
(PBRs) can be purified by immunoprecipitating a specific protein and sequencing its RNA 
cargo8,9. In addition, the cellular repertoire of polyadenylated RNA-binding proteins can be 
recovered by UV crosslinking RNA-RBP complexes, capturing RNA by oligo(dT), and 
subsequently identifying bound proteins10Ð12. However, current methods to study PBRs are 
challenging to scale up for a systems-wide analysis of RBPs and PBRs, while oligo(dT)-based 
purification requires a very large amount of starting material, complicating its application in 
dynamic conditions13. Furthermore, the requirement for polyA-tails means that oligo(dT)-based 
methods cannot be used for bacterial systems or eukaryotic non-polyadenylated RNAs. 
Published methods based on incorporation of modified nucleotides have tried to address these 
limitations, but they can introduce biases due to transcription-dependent nucleoside-
incorporation14Ð16. 
 We have developed a method based on Acidic Guanidinium Thiocyanate-Phenol-
Chloroform (AGPC) phase partition, that we name Orthogonal Organic Phase Separation 
(OOPS). AGPC purification enables unbiased recovery of RNA species17,18, by generating two 
distinct phases: RNA migrating to the upper aqueous phase and proteins occupying the lower 
organic phase. UV crosslinking at 254 nm generates RNA-protein adducts that combine the 
physicochemical properties of both molecules and migrate to the aqueous-organic interface19 . 
We hypothesized that isolation of the interface would enable specific recovery of RBPs or PBRs 
by digesting the reciprocal component of the adduct. 
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 Here, we report validation and application of OOPS. Separation of free and protein-
bound RNA provides a way to quantify the proportion of RNA crosslinked to protein, enabling 
precise UV dosage optimisation. We show that OOPS recovers all crosslinked-RNA (CL-RNA), 
including lncRNA, and all crosslinked RBPs. Using the cytostatic agent nocodazole, we identify 
RNA-binding changes between arrested and released cells for metabolic enzymes and splicing 
regulators. Finally, we characterise the first bacterium RNA-interactome, confirming that OOPS 
can retrieve RNA-RBPs in any organism. 
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Results  
  
Recovery of protein-bound RNA 
Cell lysis in Acidic Guanidinium Thiocyanate-Phenol followed by addition of chloroform 
produces two distinct phases: an aqueous (upper) phase containing RNA and an organic (lower) 
phase containing proteins. We hypothesized that UV-crosslinking at 254 nm would produce 
stable RNA-protein adducts that would be retained at the interface between the phases (Figure 
1a). CL-RNA was recovered from the interface by protein digestion using proteinase-K and 
extraction from the aqueous phase of a subsequent phase separation (Figures 1a-b, online 
methods). RNA migration from the interface to the aqueous phase after protein digestion 
indicates that its previous presence at the interface was protein binding-dependent. We observed 
a UV dose-dependent migration of RNA from the aqueous phase to the interface, saturating at 
approximately 75% of the total RNA content (Figures 1b; Figure S1a). This indicates that all 
crosslinked RNAs can be recovered from the interface. The size profile of CL-RNA resembles 
total free-RNA of a non-crosslinked sample (NC), with the aqueous phase of the CL sample 
containing free small RNAs (Figure S1b), suggesting that small RNAs may be less frequently 
crosslinked with proteins. 
 We compared the relative abundance of RNAs in crosslinked and non-crosslinked 
samples using RNA-seq. Ribosomal RNA was depleted and total RNA-seq carried out on 
samples exposed to varying UV dosages (150-400 mJ/cm2; Figure S1c). The abundance of RNA 
species in CL-RNA and NC-RNA samples was similar, with protein-coding mRNAs 
predominating (Figures 1c, S1d). Crucially, the Pearson correlation between CL and NC samples 
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was as high as that in crosslinked samples (median correlations are 0.89 and 0.92, respectively; 
Figures 1d, S1e) and as RNA size does not affect abundance in the interface post-CL, these data 
suggest that all crosslinked RNAs over 60 bp are recovered without any systematic bias (Figure 
S1f).  
 Despite the high correlation between RNA abundance in CL and NC samples, we 
observed an overall reduction of coverage in the 3Õ UTRs of mRNAs (Figures 1e) and a loss of 
coverage at discrete positions (Figure 1f). We hypothesized that this was due to steric hindrance 
of reverse transcription at sites of RNA-protein crosslinking, as protein-RNA binding occurs 
frequently within the 3Õ UTR20. We therefore applied a sliding window approach to identify Ôloss 
of coverageÕ sites in the CL samples transcriptome (supplementary note). Loss of coverage 
occurs more frequently in mRNA 3Õ UTRs and sites significantly overlap with ENCODE eCLIP 
protein-binding peaks21, confirming that they represent protein binding (Figure 1g, S1g). An 
alternative explanation is that adjacent uracils can photo-dimerize with 254 nm UV, generating 
adducts that block reverse transcription22. Regions of RNA with high uracil content, which 
preferentially crosslink to proteins at 254 nm, are more likely to contain a detectable loss of 
coverage, but adjacent uracils have no effect (Figure S1h). Protein-RNA crosslinking is the most 
likely cause of observed differences in read coverage and OOPS can therefore identify protein-
binding footprints. 
 
Identification of discrete protein-binding sites was restricted to coding genes since these are 
more highly expressed. We also manually inspected highly expressed lncRNAs and observe a 
loss of coverage at Small nucleolar RNA host gene 16 (SNHG16) and RNA Component of 
Mitochondrial RNA Processing Endoribonuclease (RMRP; Figure 1h & S1i). RMRP has two 
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functions: initiating mitochondrial DNA replication and RNA processing. The 5Õ site we identify 
matches the previously identified binding sites for the multi-function RBP HuR23, which 
promotes RMRP migration from the cytoplasm to the mitochondria24. However, confirmation 
that this loss of coverage is directly due to HuR binding needs an orthogonal approach.  
 
Recovery of RNA-binding proteins 
Next, we identified proteins crosslinked to RNA. Notably, this required less than 1% of the cells 
needed in previous RBP-capture methods10,25 (online methods). First, we used stable isotope 
labeling by amino acids in cell culture (SILAC)26 to determine the relative abundance of proteins 
from CL and NC U2OS cells in the same OOPS interface (Figure 2a; online methods). Repeated 
phase separation removed non-crosslinked proteins with three repeat separations optimal 
(Figures 2b, S2a, supplementary table 1). As glycosylated proteins share the physicochemical 
properties of RNA-protein adducts, their presence at the interface is CL-independent. In contrast, 
non-glycosylated proteins show a similar CL-enrichment, whether or not they are GO-annotated 
as RBPs (Figures 2b). These data confirm that crosslinking enriches RBPs in the interface. 
 Excluding glycoproteins, 73% of proteins were enriched at the 3rd interface post UV-
crosslinking (Figure S2b,d,e). A similar proportion of proteins were enriched with a lower UV 
dosage (150 mJ/cm2; Figure S2e). CL-enriched proteins showed a clear over-representation of 
RNA-related GO terms (Figure 2c). Within the CL-independent proteins, after accounting for 
protein abundance, there was a clear over-representation of RNA-binding GO terms (Figure 2d), 
suggesting that CL-enrichment alone is not sufficient to distinguish free proteins from RNA-
bound proteins. 
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 In order to establish that the presence of the proteins at the interface was RNA-
dependent, we treated the interfaces with ribonucleases (RNase), and measured protein migration 
to the organic phase (Figure 2e; online methods, Figures S2f-g). Proteins that migrated to the 
organic phase included those that were CL-independent, suggesting their presence in the 
interface is RNA-dependent, but their interaction with RNA was stable even in the absence of 
CL (Figure 2f, S2h). Moreover, proteins not annotated as RBPs show similar RNase sensitivity 
to those annotated as RBPs, suggesting they may be undiscovered RBPs (Figure 2g). In contrast, 
glycoprotein abundance at the interface was unaffected by RNase (Figure S2i). Since the 
presence of glycoproteins at the interface was also CL-independent (Figure 2i), we excluded 
them from downstream analyses. Ninety-three percent of proteins in the organic phase were 
RNase sensitive, whereas those absent were largely RNase insensitive (Figure 2h).  Ninety-six 
percent of proteins extracted from the organic phase showed an enrichment following RNase 
treatment (Figure 2i) and a clear over-representation of GO terms related to RNA binding 
(Figure S2j). Moreover, canonical RBPs were in the organic phase after RNase treatment (Figure 
S2f, supplementary note). Together, these experiments in U2OS cells show that RNase treatment 
is necessary. Similar results were found in HEK293 cells (Figure S2c-e and g-i).  
 
OOPS identifies canonical and novel RBPs  
RBPs identified using OOPS were compared with those from oligo(dT) RBP-Capture analysis. 
Eighty-three percent of proteins identified by RBP-capture in U2OS cells were also identified by 
OOPS (Figure 3a, S3a). For proteins identified using only one method, there was significant 
over-representation of GO-annotated RBPs (p-value < 2.2e-16, Fisher's Exact Test). We applied 
OOPS to MCF10A (a cell line derived from a healthy individual) and HEK293, and observed a 
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ÒcommonÓ RBPome of 759 proteins in all 3 cell lines (Figure 3b, S3b, supplementary table 2). 
Interestingly, the 264 proteins that were specific to the tumour-derived cell lines had an over-
representation of cell cycle RBPs (Figure S3c), indicating previous RBP cataloging experiments 
in these cell lines may have identified RBPs with limited RNA binding in non-tumour cells. A 
comparison of the 1838 proteins from the 3 cell lines used in this study with all previous human 
RBP-capture data, showed 71% identity (Figure 3c). In addition, OOPS identified 80% of the 
proteins isolated by polyA-independent RICK15 and CARIC14 methods (Figure S3d-e). These 
results indicate that OOPS recovers most of the annotated RBPome, including proteins that do 
not bind poly-adenylated RNAs.  
 As expected, OOPS RBPs show an over-representation of GO terms describing all forms 
of RNA-binding, including 5Õ and 3Õ UTR sites, and single and double-stranded RNA-binding 
(Figure 3d, S3f-g). Previously unknown RBPs identified by OOPS show an over-representation 
of GO terms related to mRNA transport and RNA localisation (Figure 3e, S3h). We projected 
OOPS RBPs onto our published hyperLOPIT data27, which identifies the average localisation of 
proteins, as an initial indication of the subcellular distribution of the RNA-bound fraction. 
Known RBPs mainly localised to the nucleus, mitochondria, cytosol and large protein complexes 
(e.g. ribosomes; Figure 3f), whereas previously undetected RBPs were more broadly distributed 
with a greater proportion of membrane proteins and proteins of indeterminate localisation 
(Figure 3f). Since membrane proteins are generally underrepresented in mass spectrometry 
experiments, we performed a crude cell fractionation to separate cellular compartments into 3 
fractions: Òheavy membranesÓ (e.g. nucleus, mitochondria), Òlight membranesÓ (e.g. 
endoplasmic reticulum, plasma membrane, etc.) and ÒcytosolÓ (Figure S3i, supplementary note) 
and confirmed that transmembrane domain-containing RBPs were more abundant in membrane 
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fractions (Figure S3j). RBPs were detected from all fractions with the membrane fractions 
yielding more previously unknown membrane-RBPs and RBPs that are known to function in 
RNA trafficking (Figures 3f, supplementary table 3). Most of the trafficking RBPs are related to 
the nuclear pore complex and the transport between nucleus and cytoplasm, but we also 
identified Unconventional Myosin-1C (MYO1C) which is involved in the movement of GLUT4-
containing vesicles to the plasma membrane28,29 and associated with the RNA polymerase II in 
the nucleus30. Our hyperLOPIT data indicates the steady-state localisation of MYO1C is in the 
secretory pathway, suggesting its RNA binding may have a role in RNA trafficking. Combining 
OOPS with fractionation thus recovers RBPs from previously underrepresented compartments.  
 
High-throughput validation of RBPs  
To validate the identified RBPs and map their RNA-binding sites, we developed a method to 
identify RNA-binding sites based on RBD-map25 (online methods; Figure 4a). The RNA-peptide 
enrichment techniques used were orthogonal to OOPS to provide independent validation of RNA 
binding capacity. Detected trypsin peptides can be mapped to the Lys-C RNA-peptide to 
determine the RNA binding region. Where possible, this region is further refined based on the 
presence/absence of expected trypsin peptides across the Lys-C peptides since trypsin RNA-
peptides will not be identified due to the variable mass shift of the RNA-peptide adduct (Figure 
S4a-b; see online methods). Not all RNA binding sites are amenable to the sequential LysC-
Trypsin digestion approach due to the requirements for relative positions of lysine and arginine 
residues (Figure S4a). Despite this, we identified discrete putative RNA-binding sites in 544 
(40%) of OOPS U2OS proteins using the adjacent peptides. This validation rate compares 
favourably with the 30% of RBP-Capture proteins where an RNA binding site could be 
 9 
identified via sequential digestion using RBD-map25. As expected, putative binding sites were 
more easily identified in proteins with a higher abundance in the interface, with a binding site 
identified for 59% of the most abundant novel RBPs (Figure 4b, supplementary table 4).   
 To confirm the specificity of our approach, we focused on proteins containing annotated 
RNA-recognition motifs (RRM)s, and observed a substantial overlap between identified sites and 
RRMs (Figure 4c). To further test these sites, we inspected published structures of RBP-RNA 
complexes. For example, the crystal structure of the glycyl-tRNA synthetase in complex with 
tRNA-Gly31 confirms that the detected binding site is less than 4  from the tRNA (Figure 4d). 
We further observed protein-RNA contacts in 17 proteins of the ribosome quality control 
complex structure previously detected using RBP-Capture, together with a novel RBP detected 
by OOPS32 (Figure S4c). Finally, we established that our method identifies known RNA-binding 
domains in GO annotated RBPs, including the canonical RRM and KH domains, and non-
canonical helicase C-terminal33,34 and DZF25 domains (Figure 4e). Alongside these non-
canonical RNA-binding domains, we identified multiple NAD-binding domains. These included 
two sites within the NAD-binding pocket of GAPDH35, which confirmed previous RNA-binding 
site predictions based on in vitro experiments36 (Figure 4f). Importantly, proteins with assigned 
RNA binding sites include some pharmacological targets. We found 21 proteins with known 
inhibitors in the IUPHAR/BPS Guide to Pharmacology37, 5 of which are targets of currently 
approved drugs. Analysis of structural information on these drug targets revealed that the 
detected RNA binding sites overlapped with the binding sites of the antiviral ribavirin to 
IMPDH2 (Figure S4d) and of antitumoral PARP1 inhibitors like rucaparib (Figure S4e). This 
surprising observation of shared interaction sites for RNA and drugs indicates that future studies 
would benefit from considering the RNA-binding role of these proteins. 
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Assessment of RNA-binding in a dynamic system 
Next, we applied OOPS to a dynamic system using a microtubule depolymerizing agent. 
Microtubule depolymerizing drugs arrest cells in prometaphase by inhibiting chromosome 
alignment and segregation, and affect a wide range of other cellular processes like intracellular 
transport and mitochondrial replication38Ð43.  
 U2OS cells were arrested with nocodazole and dynamic changes in RNA-binding were 
determined following a short (6 h) and long recovery (23 h) using TMT quantification (Figures 
5a & b, S5a and online methods). These experiments required only 0.07 m2 of cell culture, 
compared to the 19-27 m2 that would be required using RBP-Capture10,11.  As expected, we 
observed increased abundance of spindle proteins at 0 h relative to 6 h, demonstrating that 
nocodazole arrested cells at the spindle checkpoint (Figure S5b). Quantifying protein abundance 
in OOPS and total cell lysates of the same sample (Figure 5b) revealed changes in RNA-binding 
independent from concurrent changes in total protein abundance. Interestingly, changes in 
OOPS-enriched protein abundance frequently did not correlate with variations in total protein 
abundance, suggesting that specific RBPs bind RNA differentially in different cell-cycle stages 
(Figure 5c, supplementary table 5).  
 
To better understand protein dynamics, we used a linear model framework to identify proteins 
with changes in RNA-binding, taking into account their total abundance (see online methods). 
We focused on changes occurring between arrested cells and 6 h post-release. KEGG-pathway44 
and GO term over-representation analysis identified pathways with altered RNA binding 
between arrest and release (Figure S5c, S6e). Open mitosis is associated with a global inhibition 
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of RNA processing, including splicing and translation45,46. In agreement, 20/23 tRNA 
synthetases detected show lower RNA binding during nocodazole prometaphase arrest, 
suggesting a coordinated decrease in aminoacyl-tRNA availability (Figure 5Sd).  Conversely, we 
see increased RNA binding in nocodazole arrest for components of the spliceosome (Figure S5e-
f), including SRS10, which can inhibit splicing in mitosis47. 
 Nocodazole affects mitochondrial activity and cellular metabolism42,43,48. Indeed, we 
observed an over-representation of proteins involved in metabolic processes including pyruvate, 
fatty acid and amino acid metabolism, and glycolysis in the proteins with increased RNA binding 
after release which was maintained at 23 h (Figure 5d, S5c, S6e). To further explore the effect of 
nocodazole arrest/release on metabolic enzyme RNA binding we carried out an additional 
experiment using a complementary approach, thymidine-nocodazole arrest (Figure S6). 
Comparing arrest/release cells with a non-treated population we found a similar RNA binding 
profile for mitochondrial and metabolic proteins between non-treated and arrested cells. The 
increase in the RNA binding capacity of these proteins post-release points to a gain of RBP 
activity after the disruptive effects of nocodazole on microtubule formation dissipate. 
 
Many metabolic proteins have been described as eukaryotic RNA-binding proteins 12,49,50. 
However, this is the first demonstration, to our knowledge, of dynamic RNA-binding for these 
RBPs.   
 
OOPS characterisation of the Escherichia coli RBPome 
OOPS is not limited to polyadenylated RNA so we used it to obtain the RBPome of E. coli 
(Online methods). We detected 364 proteins (Figure 6a) in all 5 replicates, which represents  
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~8% of the predicted K-12 strain proteome 51, and is s similar to the proportion obtained in 
eukaryotic cells. We recovered 87/176 GO annotated RBPs (Figure 6b, supplementary table 2) 
and observed that the over-represented GO terms for OOPS RBPs are related to RNA binding 
including "rRNA binding", "tRNA binding" and the more general "nucleic acid binding" (Figure 
6c). Furthermore, of the 277 novel OOPS RBPs reported here, we find a clear enrichment for 
RNA-associated GO-terms, mainly relating to tRNAs or ncRNAs (Figure 6d). However, 234/364 
OOPS RBPs are not annotated with an RNA-related GO term, suggesting OOPS can reveal new 
RBP functions in prokaryotes. 
 
Recent observations suggest that in E. coli, transcription and translation are not always linked 
and RNA can be sequestered in helix-like structures, or be localized to the poles or the middle of 
the cell, or distributed near the plasma membrane52,53. Interestingly, we found RBPs that follow 
these RNA localisation patterns (figure 6e), suggesting their potential implication in bacterial 
subcellular RNA organization. 
 
Many of the glycolytic enzymes that bind RNA in H. sapiens, also bind RNA in E. coli 
(Figure 6f). Enolase 1 and Pyruvate kinase, detected in previous RBP-capture studies were 
identified as RBPs by OOPS in E. coli. Furthermore, GAPDH and PKG, previously described as 
low-confidence candidate RBPs in human by RBP-Capture, and phosphoglycerate mutase, a 
glycolytic protein not previously identified in any human RBP-capture, were also found as RBPs 
in our human and bacteria studies.   
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Discussion 
OOPS retrieves both crosslinked RNAs representing the complete cellular transcriptome and 
their crosslinked RBPs. Our results agree with orthogonal data from previous RBP identification 
methods. Importantly, OOPS detects new RBPs from underrepresented subcellular 
compartments, identifies specific RNA-protein interactions, characterises dynamic systems and 
can interrogate bacteria. 
 Although OOPS recovers RNAs in an unbiased manner from both the aqueous phase and 
the interface post-UV crosslinking, we observe an underrepresentation of small RNAs (sRNAs) 
in the PBR fraction. One explanation is that tRNAs, one of the most abundant sRNA species, are 
less frequently protein-bound, as has been observed in bacteria54. Overall, sRNAs have a lower 
probability of UV crosslinking to proteins, as their shorter length results in fewer simultaneous 
interactions. Despite this, we consistently found sRNA-binding proteins in both human and 
bacteria, including canonical (Hfq) and recently discovered (ProQ) E. coli sRNA binding 
proteins55. Although we primarily performed RNA-Seq to demonstrate that OOPS recovers all 
crosslinked RNAs, we were further able to identify putative protein binding sites, including 
within lncRNAs. With increased read coverage at lncRNAs by depletion of mRNAs, enrichment 
of lncRNAs56, and/or increased overall sequencing depth, it would be possible to provide a wide-
scale assessment of protein binding on lncRNAs which would help prioritise functional studies 
of lncRNAs. 
 OOPS exploits the separation of macromolecules by their physicochemical properties. As 
such, glycoproteins and RNA-protein adducts cannot be distinguished since glycans and RNAs 
are hydrophilic polymers. Our observation that the interface abundance of most glycoproteins is 
CL-independent and RNase insensitive suggests that they do not bind RNA. Despite this, it is 
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interesting to note that 17/21 glycoproteins enriched by CL are localised to the exosome (a RNA-
rich compartment57Ð59) and include 4 known RNA binding glycoproteins10,60. To completely 
catalog RNA-binding glycoproteins, it would be necessary to remove glycans. Achieving this in 
a manner that does not degrade RNA is non-trivial. We therefore took a conservative approach 
and discounted glycoproteins from our analyses. 
 Crosslinking-based detection of RBPs is based on proximity of RNAs and proteins. 
Currently, proteins crosslinking to RNA are referred to as RBPs, since UV crosslinking occurs at 
zero distance, implying binding. However, highly abundant proteins are more likely to contact 
RNAs at random. Therefore, characterisations of the RBPome inferred by UV crosslinking-based 
methods need, at a minimum, to account for the abundance of proteins in the cell, as we do here. 
Moreover, since some proteins may interact non-functionally with RNA, the functional relevance 
of some catalogs should be considered with caution19.  Dynamic experiments provide one 
method to interrogate the biological function of RNA-protein interactions and can uncover 
system-wide changes in RBPs.  
One of the most striking findings presented here is the coordinated increase in RNA-
binding of metabolic enzymes following release from nocodazole arrest. Considering the 
previously described regulation of the thermal stability of glycolytic proteins in response to 
nocodazole arrest48, and the reported repression of translation by GAPDH in response to changes 
in glycolytic flux61, our results provide further evidence for a possible link between metabolism 
and RNA binding. Many metabolic proteins have been described as RNA-binding proteins, 
although this remains a controversial proposition12,49,50. Here, we confirmed that the presence of 
glycolysis and TCA cycle-related proteins in OOPS interfaces is CL-dependent and RNase 
sensitive according to our SILAC experiments (Figure S5g), supporting their capacity to interact 
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with RNA. In particular, GAPDH has been shown to bind to a range of RNA species including 
tRNAs, AU-rich elements, and TERC62,63. In vitro experiments suggest binding occurs within its 
NAD-binding crevice, but this has not been observed in vivo36,62,64. Here, we provide the first in 
vivo evidence of GAPDH RNA binding in the NAD-binding crevice. 
 Subcellular transcriptome organization has been proposed to contribute to protein 
localization in eukaryotes65. In bacteria, spatial transcriptome distribution has historically been 
underappreciated but it now appears RNA may adopt discrete distributions52,53. close to the 
membrane, in a helical arrangement, close to the poles, or medial. Moreover, RNA distribution 
may relate to the localisation of their protein product. For example, RNA proximity to the 
plasma membrane has been found to be more prevalent in the transcripts that code for membrane 
proteins, due to their localized translation at the membrane66. Here we find that the peripheral 
membrane protein SecA is an RBP. Interaction between SecA, an ATPase component of the 
bacterial protein translocase system, and the ribosome, is thought to be mediated by a protein-
protein interaction with the ribosomal L23 protein67,68. However, our data suggest that SecA may 
also directly interact with RNA, making it a candidate to localise RNA to the membrane. 
Moreover, we further determined that proteins known to follow helical, distal, and medial 
distributions, such as MreB69, MinD70,71 or FtsZ72, can interact with RNA, making them 
candidates for future targeted studies of RNA localisation. 
 OOPS is a highly-efficient, low-cost method for the isolation of RNA-protein complexes 
in any organism, enabling the analysis of both the RNA and protein components. This simple 
method will make RNA-protein interaction studies more accessible. We hope this will foster a 
systems biology view of their function by permitting the study of their dynamic properties. 
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Figures 
Figure 1. OOPS recovers protein-bound RNAs. 
(a) Schematic representation of the OOPS method to extract protein-bound RNA. Cells are 
crosslinked to induce RNA-proteins adducts which are drawn simultaneously to the organic and 
aqueous phases in Acid Guanidinium-Phenol-Chloroform (AGPC) and thus remain at the 
interface. Protease digestion and a further AGPC separation yields RNA in the aqueous phase.  
(b) Relative proportions of free RNA (aqueous phase) and protein-bound RNA (PBR; interface) 
with increasing UV dosage. Data shown as mean +/- SD of 3 independent experiments. 
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(c) Relative proportions of RNA-Seq reads assigned to Ensembl gene biotypes for 400 mJ/cm2 
CL and NC samples. 
(d) Correlation between gene abundance estimates for NC replicate 1 and 400 mJ/cm2 CL 
replicate 1. Blue dashed lines represent a 10-fold difference. Red dashed line represents equality. 
(e) Meta-plot of read coverage over protein-coding gene-model. Reduced coverage observed for 
400 mJ/cm2 CL samples in the 3' UTR. 
(f) Read coverage across ACTB for CL (400 mJ/cm2) and NC replicates. Red boxes denote 
regions with consistently reduced coverage in CL. 
(g) Relationship between the number of eCLIP proteins with a peak in a sliding window and the 
probability of the window being identified as a protein binding site. For random shuffle, the 
center value is the mean and error bar is 2 standard deviations, n = 100 iterations.  
(h) Read coverage across RMRP for CL (400 mJ/cm2) and NC replicates. Red boxes denote 
regions with consistently reduced coverage in CL.  
Non-crosslinked=NC, Crosslinked=CL.  
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Figure 2.  OOPS for RBP recovery. 
(a) Schematic representation of the SILAC experiment used to determine the effect of UV 
crosslinking on protein abundance in the interface and the effect of additional phase separation 
cycles to wash the interface. Equal quantities of cells +/- UV crosslinking are labelled with 
SILAC and mixed prior to OOPS. RNA bound proteins are expected to have a positive CL vs 
NC ratio. Contaminants are expected to be equally abundant in CL and NC. 
(b) Protein CL vs NC ratios for the 1st to 4th interfaces. Infinite ratios (not detected in NC) are 
presented as pseudo-values in blue box. GO:RBP = GO annotated RNA binding protein. 
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(c) Top 10 molecular function GO terms over-represented in proteins enriched by CL in the 3rd 
interface. BH adj p-value = Benjamini-Hochberg adjusted p-value. P-value obtained from a 
modified hypergeometric test to account for protein abundance (see online methods).   
(d) As per (c) for proteins not enriched by CL in the 3rd interface. 
(e) Schematic representation of the SILAC experiment to determine protein abundance in the 3rd 
interface and 4th organic phase following RNase treatment. Equal quantities of cells were UV 
crosslinked and RNA-protein adducts enriched by OOPS +/- RNase before combining the 
samples for a final phase separation in which both the interface and the organic phase are 
collected. Proteins from RNase treated cells will be depleted from the interface and enriched in 
the organic phase. 
(f) Protein CL vs NC ratio and RNase vs control ratio in the interface. Red box denotes proteins 
which are not CL-enriched and not depleted by RNase. The blue regions surrounding the graph 
denote ratios which cannot be accurately estimated as the protein was only detected in one 
condition and therefore a pseudo-value is presented. 
(g) RNase vs control ratio in the interface for GO annotated RBPs and other OOPS RBPs 
(h) Protein RNase vs control ratio in the interfaces for proteins identified in the 4th step organic 
phase. Red line = equal intensity in RNase-treated and control. 
(i) Proportion of proteins enriched in the organic phase following RNase treatment. Proteins 
detected in both +/- RNase conditions but with insufficient peptides to test for significant 
enrichment are excluded. 
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Figure 3. RBPs identified using OOPS.   
(a) Overlap between OOPS, RBP-Capture and GO-annotated proteins for U2OS cells. Proteins 
were restricted to those expressed in U2OS. 
(b) Overlap between proteins identified with OOPS from U2OS, HEK293 and MCF10A. 
Proteins were restricted to those expressed in all cell lines. 
(c) Overlap between the union of OOPS RBPs identified in the 3 cell lines in (b), all published 
RBP-Capture studies, and GO annotated RBPs. Proteins were restricted to those expressed in all 
3 OOPS cell lines. 
(d) Top 10 molecular function GO terms over-represented in the proteins identified in U2OS 
OOPS. BH adj p-value = Benjamini-Hochberg adjusted p-value. P-value obtained from a 
modified hypergeometric test to account for protein abundance (see online methods). 
(e) As per (d) for novel U2OS RBPs identified by OOPS. 
(f) HyperLOPIT projections of protein steady state localisation. Left: Canonical subcellular 
localisation markers indicated in colour as shown. Right: Highlighted RBPs shown as black 
asterisks. GO RBP = GO annotated RBP. Lm = Light membrane-enriched fraction. C/o = 
Cytoplasm/Other fraction. Annotated proteins in each fraction were detected in at least one of 5 
repeat experiments. 
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Figure 4. Crosslink site analyses validates OOPS RBPs. 
(a) Schematic representation of the sequential digestion method used to identify the RNA-
binding site. RNA-protein adducts are extracted from the interface and digested with Lys-C to 
yield RNA-peptides which are subsequently enriched by silica affinity column or ethanol 
precipitation. Enriched RNA-peptides are treated with RNases followed by trypsin digestion. 
Peptides containing the UV-crosslinked nucleotide/RNA are retained by a TiO2 affinity column 
and the unbound fraction containing the peptide sequences adjacent to RNA crosslinking site is 
analysed by LC-MS/MS. Red=peptides containing site of crosslinking. Green=peptides adjacent 
to the RNA-binding site peptide. 
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(b) Proportion of OOPS RBPs in which a putative RNA-binding site was identified. Proteins 
separated into GO annotated RBPs and novel RBPs, and by their abundance at the OOPS 
interface. 
(c) Distance of putative RNA-binding sites to the nearest RRM. Smaller putative RNA-binding 
sites are closer to RRM. Counts for each size range shown above bars. 
Analysis restricted to proteins with an RRM. 
(d) Crystal structure of Glycyl-tRNA synthetase in complex with tRNA-Gly (PDB ID 4KR2). 
RNA is shown as transparent lime ribbon; Glycyl-tRNA synthetase is shown in a cyan 
transparent cartoon representation. The putative RNA binding peptide is shown in an opaque 
representation and RNA and protein residues at 4  or less from each other are shown as lime 
and cyan sticks respectively. 
(e) The number of putative RNA-binding site which intersect an Interpro-annotated protein 
domain. Domains classified as RNA or nucleotide binding or other. 
(f) Crystal structure of GAPDH complexed with NAD (PDB ID 4WNC). GAPDH is shown as a 
cyan transparent cartoon; putative RNA binding peptide is shown in an opaque representation. 
Residues at 4  or less from NAD (yellow sticks and surface representation) are shown as cyan 
sticks. 
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Figure 5. RBP-ome after nocodazole arrest.  
(a) Left: schematic representation of the nocodazole arrest/release experiment. Cells were 
analysed after 18 h nocodazole arrest and after a 6 h or 23 h release from the treatment release. 
Right: relative proportions of cells in G1, S and M phase for cells synchronised at each time-
point (shown as the mean +/- SD of 3 independent experiments) 
 (b) Schematic representation of protein extraction for nocodazole-arrest experiment. Total 
proteomes were extracted from cell lysates and RBPs were extracted following OOPS proteome 
method. 
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(c) Protein abundance from total proteome and OOPS extractions. Abundance z-score 
normalised within each extraction type. Proteins hierarchically clustered across all samples as 
shown on left  
 (d)  Protein abundance for groups of overlapping KEGG pathways over-represented in proteins 
with a significant increase in RNA-binding at 6 h vs 0 h. Individual proteins with a significant 
increase in RNA binding in 6 h vs 0 h are highlighted in green  
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Figure 6. E. coli bacterial RBPome.  
(a) Overlap between RBPs identified in 5 independent OOPS replicates. 
(b) Overlap between E.coli OOPS RBPs and GO annotated RBPs. 
(c) Top 10 molecular function GO terms over-represented in E.coli OOPS RBPs. BH adj p-value 
= Benjamini-Hochberg adjusted p-value. P-value obtained from a modified hypergeometric test 
to account for protein abundance (see online methods). 
(d) As per (c) for all GO terms over-represented in novel E.coli OOPS RBPs. 
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(e) Schematic representation of OOPS novel RBPs that follow 4 distinct localisation patterns in 
which RNA has been found. 
(f) RNA-binding capacity of glycolysis/gluconeogenesis proteins. Proteins coloured by 
pathways; blue text = only glycolysis, orange text = only gluconeogenesis. Asterisks = increased 
RNA-binding after release from nocodazole arrest. GO:RBP=GO-annotated RBP. Orange filled 
circle = protein observed in the dataset indicated. Dark blue fill = protein in human RBP-Capture 
experiments but listed as a lower-confidence ÒcandidateÓ RBP. Empty circle = protein present in 
species but not observed in dataset. Where paralogs exist, filled circles indicate the detection of 
at least one paralog. Thick black line indicates an RNA-binding site was identified in the 
sequential digestion experiment.  
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Online Methods 
 
Cell culture: 
U-2 OS (U2OS) and MCF 10A cells were obtained from the American Type Culture Collection 
(ATCC). HEK-293 were kindly provided by Dr. Johanna Rees (University of Cambridge). U2OS and 
HEK-293 cells were cultured in McCoyÕs 5A and DMEM (Gibco-BRL) media respectively, 
supplemented with 10% fetal bovine serum (Gibco-BRL). MCF 10A were maintained in MEBM media 
(Lonza/Clonetics) supplemented with 10 ng/ml of cholera toxin (Sigma-Aldrich). All cells were 
maintained at 37 ¼C and 5% CO2 and regularly tested for mycoplasma contamination with negative 
results. 
 
E. coli K-12 DH5a strain (Thermo Fisher Scientific), was cultured in LB Broth (Thermo Fisher 
Scientific) at 37 ¼C. All E. coli experiments were done at stationary phase after 16 h of cell growth. 
 
Orthogonal Organic Phase Separation in human cells: 
Cells were cultured in 6 cm diameter dishes (28.2 cm2) for catalog experiments, or 10 cm diameter 
dishes (78.5 cm2) for dynamic experiments, until a maximum of 90% of confluence was reached, using a 
single dish per replica and condition. Cells were washed twice with PBS and supernatant removed by 
pipetting. In non-crosslinked controls, cells were immediately lysed by scrapping in Acidic 
Guanidinium-Thiocyanate-Phenol (Trizol, Thermo Fisher Scientific), and the homogenate transferred to 
a new tube. In crosslinked samples, UV-crosslinking was performed on PBS-washed cells by UV-
irradiation at 254 nm (CL-1000 Ultraviolet Crosslinker; UVP). Immediately after crosslinking, cells 
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were scraped in Trizol and the homogenized lysate was transferred to a new tube and incubated at room 
temperature (RT) for 5 min to dissociate unstabilised RNA-protein interactions. For biphasic extraction, 
200 µL of chloroform (Fisher Scientific) were added, phases were vortexed and centrifuged for 15 min 
at 12,000 x g at 4 oC. The upper aqueous phase (containing non-crosslinked RNAs) was transferred to a 
new tube, and RNA precipitated following manufacturer instructions. The lower organic phase 
(containing non-crosslinked proteins) was transferred to a new tube and proteins precipitated by addition 
of 9 volumes of methanol (Fisher Scientific). Interface (containing the Protein-RNA adducts) was 
subjected to extra AGPC phase separation cycles, precipitated by addition of 9 volumes of methanol, 
and pelleted by centrifugation at 14,000 x g, RT for 10 min.  
For RNA analyses, the precipitated interfaces were incubated for 2h at 50 ¼C in 30 mM Tris HCl 
(pH8)/10 mM EDTA and 18 U of proteinase K (Thermo Fisher Scientific). Samples were cooled and 
released RNA was purified by standard phenol/chloroform extraction (Thermo Fisher Scientific) 
according to the manufacturer instructions. 
For RNA-binding protein analyses, the precipitated interface was resuspended in 100 µL of 100 mM 
TEAB, 1 mM MgCl2, 1% SDS, incubated at 95 ¼C for 20 min, cooled down and digested with 2 µg 
RNase A, T1 mix (2 mg/mL of RNase A and 5000 U/mL of RNase T1, Thermo Fisher Scientific) for 2-
3 h at 37 ¼C. Another 2 µg of RNase mix was added and incubated overnight at 37 ¼C, after which a final 
cycle of AGPC phase partitioning was performed and released proteins recovered from the organic 
phase by methanol precipitation.  
 
Orthogonal Organic Phase Separation in bacteria: 
E. coli cultures were grown overnight. 3 ml of culture was pelleted by centrifugation (5 min at 6000 x g, 
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RT) and washed twice with PBS. Cells were re-suspended in PBS and crosslinked in solution at 254 nm 
for 525 mJ/cm2. Crosslinked cells were pelleted again and supernatant removed by pipetting, leaving 
approximately 50 µl of PBS. 500 µl of 0.5 mm glass beads (Sigma-Aldrich) were added to each sample, 
mixed gently, frozen on dry ice and dried by sublimation for 2 h. Dried cells were disrupted by 
vortexing for 5 min, at intervals of 1 min to avoid warming the sample. 1 ml Trizol was added to each 
tube and samples were homogenized by vortexing. Supernatant (avoiding glass beads) was transferred to 
a new tube and centrifuged 5 min at 6000 x g at 4 ¼C. The supernatant was transferred to a new tube, 
leaving the unlysed cells as a pellet. Finally, OOPS was performed as described above. 
 
RNA quantification and integrity assessment: 
RNA purity was assessed by Nanodrop (Thermo Fisher Scientific). Samples with a 260/280 ratio below 
1.9 or 260/230 below 2 were discarded. RNA concentration was estimated using the Qubit RNA BR 
(Broad-Range) Assay Kit (Thermo Fisher Scientific) in the Qubit¨ 2.0 Fluorometer (Thermo Fisher 
Scientific). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer system (Agilent).  
 
RNA sequencing: 
Protein Bound RNA (PBR) and total non-crosslinked (NC) RNA were purified using OOPS or standard 
Trizol extraction respectively. All RNA samples were treated with turbo DNase (Thermo Fisher 
Scientific). Ribosomal RNA (rRNA) was depleted using RiboCop kit V1.2 (Lexogen, Greenland, NH, 
USA) according to manufacturer instructions, starting with 1 ug of RNA. Two nanograms of rRNA-
depleted NC-RNA or 8 ng of rRNA-depleted PBR were used to generate sequencing libraries using 
SENSE total RNA-Seq Library Prep kit (Lexogen). All libraries were sequenced in parallel on a 
NextSeq 500 for 75 cycles (Illumina).  
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RNA-Seq data processing and bioinformatics 
Quality control of raw fastqs was performed using FastQC 
(www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were aligned to the hg38 human genome 
and Ensembl 8773 using hisat274 with default settings and reads with MAPQ < 10 were discarded. 
Transcript quantification was performed with Salmon75 using default settings. The meta-plot of read 
coverage over gene model was obtained using the CGAT bam2geneprofile script with 
reporter=utrprofile76. For details of the identification of putative protein binding sites and the overlap 
with eCLIP data, see supplementary note. 
 
Oligo(dT) RBP-capture: 
RBP-Capture was performed according to25, with the following modifications. We used 4 x 500 cm2 
plates per condition. Oligo(dT)25 magnetic beads (NE Biolabs) were reconditioned as per 
manufacturerÕs instructions and incubated with the lysates for a second round of RBP-capture with 
eluates from the two rounds were pooled together 
 
Subcellular fractionation: 
U2OS cells from a single 80% confluent 500 cm2 cell culture dish (Sigma-Aldrich) were detached using 
trypsin without EDTA (Thermo Fisher Scientific), pelleted 5 min at 250 x g, washed with PBS, 
resuspended in 50 ml of PBS and crosslinked in solution at 254 nm at 400 mJ/cm2. Cells were pelleted 
again for 5 min at 250 x g, resuspended in 1 ml of lysis buffer (0.25 M sucrose, 10 mM HEPES pH 7.4) 
containing protease inhibitors (Roche), and lysed with a ball-bearing homogenizer (Isobiotec) on ice. 
Unlysed cells were removed by centrifugation at 200 x g, 5 min at 4 ¡C. The supernatant was transferred 
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to a new tube and centrifuged at 1000 x g, 10 min at 4 ¼C with the pellet collected as Ôheavy membrane 
fractionÕ. The supernatant was centrifuged again at 12.200 x g with the pellet collected as the Ôlight 
membrane fractionÕ. The supernatant was collected as cytosolic fraction, frozen and dried by 
sublimation by SpeedVac (Labconco). Pellets from the heavy membranes, light membranes and cytosol 
were re-suspended in Trizol and RBPome and ÒtotalÓ proteome were extracted using OOPS. 
 
Nocodazole arrest: 
Single nocodazole arrest: A single 10 cm2 diameter dish (per replica and condition) of U2OS cells at 
70% of confluence was arrested in prometaphase by direct addition of 1 µg/ml of nocodazole (Sigma-
Aldrich) to the cell culture media. 16-18 h post treatment, synchronised cells were washed twice in PBS 
and crosslinked at 254 nm at 400 mJ/cm2. Arrested cells were detached by mechanical stimulation, 
pelleted, solubilised in Acidic Guanidinium-Thiocyanate-Phenol and stored at -80 ¼C. For the post-
release 6 h and 23 h timepoints, synchronised cells were detached from the dish by mechanical 
stimulation, washed in PBS and re-seeded in media without nocodazole. Cells were then washed twice 
with PBS and crosslinked at 254 nm at 400 mJ/cm2. Cell lysates were obtained by directly scraping the 
crosslinked cells in Acidic Guanidinium-Thiocyanate-Phenol. The total proteome was extracted from the 
lysate and the RBPome was determined using OOPS (see Orthogonal Organic Phase Separation in 
human cells).  
Double thymidine-nocodazole arrest: A single 10 cm2 diameter dish (per replica and condition) of U2OS 
cells at 70% of confluence was arrested in G1/S phase by incubating the cells with 2.5 mM of thymidine 
(Sigma-Aldrich) for 18 h. After the first thymidine block, cells were washed twice with PBS and 
incubated for 16 h with media containing 100 ng/ml of nocodazole (Sigma-Aldrich). To collect our 0 h 
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timepoint, cells were washed twice with PBS and released from nocodazole arrest for 20 min before 
being crosslinked at 254 nm at 400 mJ/cm2. Cells were detached by mechanical stimulation, pelleted and 
solubilised in Acidic Guanidium-Thiocyanate-Phenol (Trizol) and stored at Ð80 ¼C. For post-release 
timepoint (6 h post-arrest), total cell lysate and OOPS preparation, cells were handled in the same 
conditions as for the single nocodazole arrest.  
A parallel cell dish was cultured for every time point and replicate to assess the arrest efficacy and the 
recovery post release by flow cytometry. DNA content per cell was analysed using the Propidium Iodide 
Flow Cytometry Kit (Abcam) as indicated by the manufacturer. Flow cytometry results were analysed 
using FlowJo 8.7, manually determining the different cell populations according with their DNA content 
(2N = G1, 2-4N = S and 4N = G2/M).   
 
Proteomic sample preparation: 
Samples were resuspended in 100 µL of 100 mM Triethylammonium bicarbonate (TEAB) (Sigma-
Aldrich), reduced with 20 mM DTT (Sigma-Aldrich) at room temperature for 60 min and alkylated with 
40 mM iodoacetamide (Sigma-Aldrich) at room temperature in the dark for at least 60 min. Samples 
were digested overnight at 37 ¼C with 1 µg of Trypsin (Promega) with the exception of samples for 
TMT labeling which were digested overnight at 37 ¼C with 1 µg Lys-C (Promega). Subsequently, 1 µg 
of modified trypsin (Promega) was added, and the samples were incubated for 3-4 h at 37 ¼C. Samples 
were then acidified with TFA (0.1% (v/v) final concentration; Sigma-Aldrich) and centrifuged at 21,000 
x g for 10 min, with the supernatant frozen at -80 ¼C until required.  
For peptide clean-up and quantification, 200 µL of Poros Oligo R3 (Thermo Fisher Scientific) resin 
slurry (approximately 150-200 µL resin) was packed into Pierceª Centrifuge Columns (Thermo Fisher 
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Scientific) and equilibrated with 0.1% TFA. Samples were loaded, washed twice with 200 µL 0.1% TFA 
and eluted with 300 µL 70% acetonitrile (ACN) (adapted from77). 10 µL was taken from each elution for 
QubitTM protein assay (Thermo Fisher Scientific) quantitation, with the remaining sample retained for 
MS. 
 
LC-MS/MS  
Supplementary table 6 details the main parameters used for each sample. 
SILAC labelling was performed according to the manufacturer's instructions by growing cells in DMEM 
media containing light (Arg0-Lys0) or heavy (Arg10-Lys8) isotopes (SILAC Protein Quantitation Kit, 
Thermo Fisher Scientific). SILAC and unlabeled samples generated from OOPS experiments in E. coli 
and MCF10A were acquired using CHarge Ordered Parallel Ion aNalysis (CHOPIN) acquisition in 
positive ion mode as previously reported78, using the Orbitrap Fusion Lumos (Thermo Fisher Scientific) 
coupled to a nanoLC Dionex Ultimate 3000 UHPLC (Thermo Fisher Scientific). Samples for direct 
assessment of RNA crosslinking site were acquired in the Orbitrap Fusion Lumos using HCD 
fragmentation and detection in the orbitrap analyser.  
TMT-11plex or TMT-10plex (Thermo Fisher Scientific) labelling from desalted peptides was performed 
according to the manufacturer's protocol. Equal amounts of desalted peptides were labelled immediately 
after being quantified with QubitTM protein assay (Thermo Fisher Scientific). Multiplexed TMT samples 
were separated into 4 fractions using Pierceª High pH Reversed-Phase Peptide Fractionation Kit 
(Thermo Fisher Scientific). TMT labeled fractions were analysed in an Orbitrap Fusion Lumos. Mass 
spectra were acquired in positive ion mode applying data acquisition using synchronous precursor 
selection MS3 (SPS-MS3) acquisition mode79. 
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Samples from Oligo(dT) capture and from subcellular fractionation were analysed in an Orbitrap nano-
ESI Q-Exactive mass spectrometer (Thermo Fisher Scientific), coupled to a nanoLC (Dionex Ultimate 
3000 UHPLC).  
All samples were analysed in a 120 min run except for TMT-labeled fractions (240 min) and RNA-
crosslinking site assessment samples (60 min). 
 
MS spectra processing and peptide/protein identification 
Raw data were viewed in Xcalibur v.2.1 (Thermo Fisher Scientific), and data processing was performed 
using Proteome Discoverer v2.1 (Thermo Fisher Scientific). The Raw files were submitted to a database 
search using Proteome Discoverer with Mascot, SequestHF and MS Amanda80 algorithms against the 
Homo sapiens database for U2OS, HEK-293 and MCF 10A cells or E. coli database, downloaded in 
early 2017 containing human (or E. coli) protein sequences from UniProt/Swiss-Prot and UniProt/ 
TrEMBL. Common contaminant proteins (several types of human keratins, BSA, and porcine trypsin) 
were added to the database, and all contaminant proteins identified were removed from the result lists 
prior to further analysis. The spectra identification was performed with the following parameters: MS 
accuracy, 10 ppm; MS/MS accuracy of 0.05 Da for spectra acquired in Orbitrap analyser and 0.5 Da for 
spectra acquired in Ion Trap analyser; up to two missed cleavage sites allowed; carbamidomethylation of 
cysteine (as well as TMT6plex tagging of lysine and peptide N-terminus for TMT labeled samples) as a 
fixed modification; and oxidation of methionine and deamidated asparagine and glutamine as variable 
modifications. Arginine (+10.008 Da) and Lysine (+8.014 Da) were also set as variable modifications in 
SILAC-labeled samples.   Percolator node was used for false discovery rate estimation and only rank 1 
peptide identifications of high confidence (FDR < 1 %) were accepted. A minimum of two high 
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confidence peptides per protein was required for identification using Proteome Discoverer, except in 
samples for RNA crosslinking site assessment.  
TMT reporter values were assessed through Proteome Discoverer v2.1 using Most Confident Centroid 
method for peak integration and integration tolerance of 20 ppm. Reporter ion intensities were adjusted 
to correct for the isotopic impurities of the different TMT reagents (manufacturer specifications). 
  
Direct assessment of RNA crosslinking site in proteins: 
Starting from the methanol-precipitated OOPS interface, proteins were digested using 1 µg Lys-C 
(Promega, Madison, WI, USA) in 100 µL of 100 mM TEAB (Sigma-Aldrich) with 1 µL of RNaseOUT 
(Thermo Fisher Scientific) overnight at 37 ¼C. Two different approaches were used to enriched RNA-
peptides:  
(i) Silica-based RNA purification using the RNeasy kit (Qiagen), according with the manufacturer's 
instructions;  
(ii) Precipitation in 80% ethanol. Two rounds of precipitations were used to further clean the sample.  
RNA-peptides were re-suspended in 100 µL of 100 mM Tris-HCl (pH 8.0)/ 2 mM MgCl2, sonicated for 
15 min and incubated at 95 ¼C for 20 min. 2 µg RNase A/T1 mix (2 mg/mL of RNase A and 5000 U/mL 
of RNase T1) was added to cooled samples, and incubated for 4 h at 37 ¼C followed by a second 
protease digestion using 1 µg trypsin (Promega) overnight at 37 ¼C. Digested samples were desalted 
with Oligo R3 as described in the Òproteomics sample preparationÓ section and dried on speedvac 
(Labconco). 
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Digests were re-suspended in 30-40 µL of 80% acetonitrile (ACN)/2% TFA containing 1 µg of TiO2 
beads (GL Sciences). The slurry was transferred into a p200 tip containing a C8 ÒplugÓ (3M Empore, 
Sigma-Aldrich) to retain the loaded TiO2 beads and the flow-through collected. The packed TiO2 was 
washed with 20 µL 80% ACN/2% TFA, then 20 µL 10% ACN/0.1% TFA and the flow-through from 
both retained. The TiO2-enriched fraction was eluted from the beads with two rounds of 20 µL of 
ammonia solution (1.5-1.8%), pH>10.5, and 20 µL of 50% ACN.  
 
Proteomics bioinformatics and data analysis 
Peptide-level output from Proteome Discoverer was re-processed with the add_master_protein.py script 
(https://github.com/TomSmithCGAT/CamProt) to ensure uniform peptide to protein assignment for all 
samples from a single experiment and identify peptides which are likely to originate from contaminating 
proteins such as keratin (see supplementary note). For quantitative experiments, peptide-level 
quantification was obtained by summing the quantification values for all peptides with the same 
sequence but different modifications. Protein-level quantification was then obtained by taking the 
median peptide abundance. For SILAC experiments, the ratio between treatment and control protein 
abundance was calculated for each sample separately and aggregated to average protein ratio. For TMT 
experiments, data analysis was performed using the MSnbase R package81. Log2-transformed protein 
abundance was centre-median normalised within each sample. For the crude fractionation experiments 
(n=5), the protein abundance was quantified by label-free quantification, averaged across the replicates 
per fraction and normalised per protein such that the sum of abundances over the 3 fractions was 1. For 
the U2OS RBP-Capture experiment, only proteins observed in all 3 CL replicates and no NC replicates 
were retained.  In crosslink-testing SILAC experiments, only proteins present in at least 2 replicates 
were retained. 
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GO terms, Interpro protein domains and KEGG pathway annotations were obtained using the R package 
UniProt.ws82. GO terms were expanded to include all parent terms using the R package GO.db83. 
Glycoproteins were identified using the Uniprot84 API with categories=PTM and types=CARBOHYD. 
Transmembrane proteins were identified using the Uniprot API with types=TRANSMEM.  
 
Statistics  
Data handling was performed with R v3.4.1 using tidyverse packages and python v3.6.5. Plotting was 
performed with the ggplot2 R package85. 
Proteins observed only in CL in at least one replicate were deemed enriched. For the RNAse-testing 
SILAC experiments, proteins only ever observed in the RNAse condition at the organic phase were 
deemed enriched. Vis versa, those only ever observed in the control condition at the interfaces were 
deemed depleted. For proteins which did not meet these criteria, all peptides observed across the 
replicates were treated as independent observations and a two-tailed Mann-Whitney-Wilcoxon Test was 
used to test whether the log2 median CL:NC or RNase:Control ratio was > 0 (enriched) or < 0 
(depleted), with a BH-adjusted p-values < 0.05 considered significant. Proteins with less than 6 peptides 
were excluded from the statistical test due to insufficient power.  
GO, InterPro and KEGG over-representation analyses were conducted using the R package goseq. This 
package was originally developed to account for the relationship between the probability of an 
differentially expressed gene in RNA-seq and the length of the gene by calculating a probability weight 
function to estimate the relationship between gene length and P(differential expression) and then 
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approximating a null distribution for the number of genes expected to be differentially expressed from a 
given set (e.g GO term) based on their length alone. An empirical p-value is then derived by comparing 
the number of observed genes to the null expectation. The package allows this approach to be 
generalised to any observation and any confounding factor. We used protein abundance since more 
abundant proteins are more likely to be detected and more likely to be detected as significantly altered in 
abundance due to relatively lower variance and thus increased statistical power. For U2OS and HEK-
293, protein abundance was derived from86 taking the maximum abundance recorded across the 
replicates. For MCF10A, we used an in-house deep proteomics data set. For E.coli, protein abundance 
was obtained from PaxDB87. Proteins not present in the above reference data sets were excluded from 
the analysis. Resultant p-values were adjusted to account for multiple testing using the Benjamini-
Hochberg88 FDR procedure. GO-terms and InterPro domains with adjusted p-value <0.01 and at least 5 
proteins were considered significantly over-represented. KEGG pathways with adjusted p-value <0.05 
and at least 5 proteins were considered significantly over-represented. Over-representation values given 
are not adjusted for protein abundance.  
For the nocodazole arrest/release experiment, proteins with a change in abundance or RNA binding were 
identified using the lm function in R. Specifically, to identify protein with a change in abundance 
between nocodazole arrest and 6 h release, total protein abundance was modelled as a function of the 
time point alone (abundance ~ timepoint). The p-values for the timepoint coefficients for each proteins 
were adjusted to account for multiple hypothesis testing according to Benjamini-Hochberg88 and 
proteins with an adjusted p-value < 0.01 (1 % FDR) were considered to have changed abundance. To 
identify proteins with a change in RNA binding between nocodazole arrest and 6 h release, protein 
abundance in the total proteome and OOPS samples was modelled as a function of the time point, the 
abundance type (total or OOPS), and the interaction between these two variables (abundance ~ timepoint 
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+ type + timepoint*type). Here, the interaction term denotes whether the abundance in OOPS and total 
follows the same pattern across the timepoints (coefficient is zero), indicating total abundance 
determines the amount of protein bound to RNA, or diverges (non-zero coefficient), indicating a change 
in RNA binding between the timepoints. The p-values for the interaction term were obtained and 
adjusted as indicated above. For the heatmap representation, protein abundances were z-score 
normalised within the total and OOPS samples separately. Hierarchical clustering was performed with 
the R hclust function using 1-SpearmanÕs rho as the distance metric and average linkage. 
For details of the identification of RNA binding sites see supplementary note. 
 
Structural Assessment of RNA-protein contacts 
In order to look for structural information to validate our direct evidence for RNA-protein contacts, the 
Uniprot IDs of the detected proteins were used to retrieve all their associated PDB IDs using the Uniprot 
Retrieve/ID mapping tool. In parallel, we retrieved information for all structures annotated as containing 
protein-RNA complexes in the nucleic acid database89. Comparison of PDB IDs common in both 
subsets revealed the structures of the ribosome quality control complex (PDB ID 3J92) and of a Glycyl-
tRNA synthetase in complex with tRNA-Gly (PDB ID 4KR2). These structures, together with the 
structure of GADPH in complex with NAD (PDB ID 4WNC), were later visualized using VMD 1.9.490. 
The Reporting Summary is available online: Life Sciences Reporting Summary 
 
Data availability  
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via 
the PRIDE91 partner repository with the dataset identifier PXD009668. 
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All sequencing data can be accessed through the European Nucleotide Archive, accession code 
PRJEB26736. 
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